Company Monitoring Page for Novo-Nordisk

latest headlines for company on cafepharma

Can Once Daily GLP-1 Lyxumia Be The Next Major Growth Driver For Sanofi?
Seeking Alpha
Wed, 04/16/14 - 09:37 am
Tags:
Lyxumia, GLP-1 agonist, Sanofi, Novo Nordisk, diabetes, Victoza
Makings of a Wide Moat in Diabetes Care
Morningstar
Fri, 03/28/14 - 11:16 am
Tags:
diabetes, Takeda, Sanofi, GSK, Victoza, Merck, insulin, Novo Nordisk, Afrezza, U300, Tresiba, Eli Lilly
Novo CEO sees improved picture for Tresiba in U.S. market
Fierce Pharma
Mon, 03/24/14 - 12:13 pm
Tags:
Novo Nordisk, Pharma CEOs, Tresiba, diabetes, Sanofi, insulin
Novo Nordisk sees chance of U.S. Tresiba launch before rival products
Yahoo/Reuters
Thu, 03/20/14 - 05:35 pm
Tags:
Novo Nordisk, insulin, diabetes, Tresiba, Lantus, Sanofi, Eli Lilly
Novo reports positive results from phase 3 trial with NovoEight
Reuters
Wed, 03/19/14 - 04:11 pm
Tags:
Novo Nordisk, NovoEight, hemophilia A
Novo Nordisk taps bankers for potential IT unit spinoff
Fierce Pharma
Tue, 03/18/14 - 12:16 pm
Tags:
Novo Nordisk, spinoffs
Europe’s Half-Empty Pharma Market
WSJ Online
Mon, 03/17/14 - 10:55 am
Tags:
Europe, Bayer, Novo Nordisk, Shire, Merck KGaA
Novo Nordisk - An Opportune Time To Book Profits
Seeking Alpha
Fri, 03/14/14 - 08:36 am
Tags:
Novo Nordisk
With Solvadi in the mix, the FDA's class of 2013 is set for chart-busting sales
Fierce Pharma
Tue, 03/11/14 - 12:00 pm
Tags:
Sovaldi, FDA, Gilead Sciences, Novo Nordisk, AbbVie, Biogen Idec
Can Diabetes Treatments Replace Patent Losses At Eli Lilly & Co?
Motley Fool
Thu, 03/6/14 - 10:17 am
Tags:
Eli Lilly, diabetes, patents, dulaglutide, GLP-1 agonist, Novo Nordisk, AstraZeneca, GSK, JNJ
FDA eases worries regarding certain diabetes medications
Yahoo/Fly on the Wall
Thu, 02/27/14 - 08:19 am
Tags:
FDA, diabetes, Merck, Januvia, Janumet, Novo Nordisk, Victoza, Bristol-Myers Squibb, Byetta, Bydureon
Who loses most in Lilly vs. Novo diabetes study? AstraZeneca
Fierce Pharma
Wed, 02/26/14 - 07:02 pm
Tags:
Victoza, Novo Nordisk, Eli Lilly, dulaglutide, diabetes, Bydureon, AstraZeneca
Lilly weekly diabetes drug succeeds vs market leader Victoza -study
Yahoo/Reuters
Tue, 02/25/14 - 08:15 am
Tags:
Eli Lilly, diabetes, Victoza, Novo Nordisk, dulaglutide
Biotech Showdown: Arena Pharmaceuticals vs. VIVUS Inc.
Motley Fool
Fri, 02/21/14 - 10:44 am
Tags:
obesity, Arena Pharmaceuticals, Vivus, Belviq, Qsymia, Novo Nordisk, Orexigen
Novo Nordisk targets Mexico for early obesity drug launch
Fierce Pharma
Wed, 02/19/14 - 12:57 pm
Tags:
Novo Nordisk, obesity, Mexico, liraglutide
Poor Pipeline Management Imperils Lilly's Future Cash Flows
Motley Fool
Mon, 02/17/14 - 03:22 pm
Tags:
Eli Lilly, diabetes, insulin, Novo Nordisk, Sanofi, oncology, Alzheimer's disease
What's Big Pharma's latest hot spot? The Middle East
Fierce Pharma
Tue, 02/11/14 - 12:00 pm
Tags:
Middle East, Merck, Merck Serono, Sanofi, Novo Nordisk, Eli Lilly, Bayer
Is There Investment Upside In The Future Of Treating Diabetes?
Seeking Alpha
Mon, 02/10/14 - 08:43 am
Tags:
diabetes, MannKind, Merck, Novo Nordisk, NeoStem, Regeneron
Novo Nordisk Gives anti-NKG2A Rights to Innate
Yahoo/Zacks.com
Thu, 02/6/14 - 06:09 pm
Tags:
Innate Pharma S.A., Novo Nordisk, anti-NKG2A
The Dream Of The Insulin Pill: Oramed Vs. Rivals
Seeking Alpha
Thu, 02/6/14 - 07:47 am
Tags:
insulin, diabetes, Oramed, oral insulin, ORMD-0801, NN1954, Novo Nordisk

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.